Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Net Cash Flow (2020 - 2025)

Oncology Institute (TOI) has disclosed Net Cash Flow for 6 consecutive years, with -$2.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 123.99% year-over-year to -$2.6 million, compared with a TTM value of -$19.7 million through Sep 2025, down 199.38%, and an annual FY2024 reading of $16.2 million, down 16.93% over the prior year.
  • Net Cash Flow was -$2.6 million for Q3 2025 at Oncology Institute, up from -$9.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $103.6 million in Q4 2021 and bottomed at -$47.4 million in Q4 2022.
  • Average Net Cash Flow over 5 years is $1.1 million, with a median of -$1.4 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 3919.58% in 2021, while the deepest fall reached 3379.02% in 2021.
  • Year by year, Net Cash Flow stood at $103.6 million in 2021, then tumbled by 145.75% to -$47.4 million in 2022, then surged by 112.56% to $6.0 million in 2023, then plummeted by 61.92% to $2.3 million in 2024, then crashed by 216.19% to -$2.6 million in 2025.
  • Business Quant data shows Net Cash Flow for TOI at -$2.6 million in Q3 2025, -$9.4 million in Q2 2025, and -$9.9 million in Q1 2025.